Combination Iron Chelation Therapy

Status Completed

Clinical Trial Summary

Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00004982
Study type	Interventional
Source	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact
Status	Completed
Phase	Phase 1
Start date	December 1998
Completion date	November 2002

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT04614779` - Long-term Clinical Study of CN128 in Thalassemia Patients	Phase 2
Completed	`NCT01158794` - Genes Influencing Iron Overload State
Recruiting	`NCT02995707` - The Effective and Safety of Thalidomide in NTDT	Phase 2
Active, not recruiting	`NCT01935661` - A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT00901199` - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload	Phase 2
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Recruiting	`NCT05508932` - Atrial Fibrillation in Beta-Thalassemia
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT03117192` - Zinc Supplementation on Cellular Immunity in Thalassemia Major	Phase 4
Completed	`NCT03095326` - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia	Phase 4
Completed	`NCT01443312` - Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Completed	`NCT00744692` - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders	Phase 1
Completed	`NCT00235391` - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload	Phase 3
Not yet recruiting	`NCT06058260` - Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
Completed	`NCT05529550` - Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
Completed	`NCT04582110` - The Role of OCTA in Patients Affected by Beta Thalassemia
Recruiting	`NCT06213402` - RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)